Advertisement
Advertisement
ARCT
Arcturus Therapeutics Holdings Inc. Common Stock
13.85
USDSponsored
-0.27
-1.91%
Sep 25, 15:59 UTC -4
Closed
After-Market
13.86
+0.01
+0.04%
ARCT Earnings Reports
Positive Surprise Ratio
ARCT beat 27 of 42 last estimates.
64%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$8.16M
/-$0.69
Implied change from Q2 26 (Revenue/ EPS)
+175.77%
/-17.86%
Implied change from Q3 25 (Revenue/ EPS)
-52.42%
/+40.82%
Arcturus Therapeutics Holdings Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, ARCT reported earnings of -0.84 USD per share (EPS) for Q2 26, beating the estimate of -1.01 USD, resulting in a 17.53% surprise. Revenue reached 2.96 million, compared to an expected 3.26 million, with a -9.32% difference. The market reacted with a +21.88% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 8 analysts forecast an EPS of -0.69 USD, with revenue projected to reach 8.16 million USD, implying an decrease of -17.86% EPS, and increase of 175.77% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Arcturus Therapeutics Holdings Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Arcturus Therapeutics Holdings Inc. Common Stock reported EPS of -$0.84, beating estimates by 17.53%, and revenue of $2.96M, -9.32% below expectations.
How did the market react to Arcturus Therapeutics Holdings Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 21.88%, changed from $6.08 before the earnings release to $7.41 the day after.
When is Arcturus Therapeutics Holdings Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Arcturus Therapeutics Holdings Inc. Common Stock's next earnings report?
Based on 8
analysts, Arcturus Therapeutics Holdings Inc. Common Stock is expected to report EPS of -$0.69 and revenue of $8.16M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.